Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 5/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18150269 | 0.87 | THRB (0.41) | THRBMAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL7232014 | 0.83 | THRB (0.40) | THRBMAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL18154544 | 0.83 | THRB (0.40) | THRBMAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL18161998 | 0.83 | ALDH1A1 (0.40) | THRBMAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL7223146 | 0.83 | AKR1B1 (0.43) | THRBKMT2AALDH1A1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL18150270 | 0.82 | THRB (0.39) | THRBMAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL7225366 | 0.81 | THRB (0.38) | THRBMAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL20807322 | 0.80 | MTNR1A (0.39) | THRBMAPTKMT2AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL18154539 | 0.80 | THRB (0.38) | THRBMAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL7232217 | 0.78 | ESR1 (0.44) | KMT2AALDH1A1KDM4EGAAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107454902-B | Chromene derivatives as phosphoinositide 3-kinase inhibitors | 奇斯药制品公司 | 2020-09-15 | — | — | CN | disclosed |
| EP-3283481-B1 | CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-03-13 | — | — | EP | disclosed |
| EP-3283481-B1 | CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-03-13 | — | — | EP | disclosed |
| US-9968604-B2 | Chromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-05-15 | — | — | US | disclosed |
| US-9968604-B2 | Chromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-05-15 | — | — | US | disclosed |
| US-9968604-B2 | Chromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-05-15 | — | — | US | disclosed |
| EP-3283481-A1 | CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2018-02-21 | — | — | EP | disclosed |
| US-20160303123-A1 | CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-20 | — | — | US | disclosed |
| US-20160303123-A1 | CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-20 | — | — | US | disclosed |
| US-20160303123-A1 | CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-20 | — | — | US | disclosed |
| WO-2016166239-A1 | CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166239-A1 | CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-20 | — | — | WO | disclosed |
| US-6509362-B2 | Cholesteryl acyl transferase (ACAT) inhibitors; treatment of hyperlipidaemia and atherosclerosis. | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2003-01-21 | — | — | US | disclosed |
| US-20020068739-A1 | New N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-06-06 | — | — | US | disclosed |
| US-6339097-B1 | FOR THERAPY OF HYPERLIPIDAEMIA AND ATHEROSCLEROSIS; CHOLESTERYL ACYL TRANSFERASE (ACAT) INHIBITORS | MERCK PATENT GMBH (DE) | 2002-01-15 | — | — | US | disclosed |
| CN-1283196-A | N-phenylamides and N-pyridylamides, process for their preparation and pharmaceutical compositions containing them | MERCK PATENT GMBH (DE) | 2001-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068739-A1 | New N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them | ACAT2, LCAT, ACAT1 | THRB 3341/4885MAPT 893/4885KMT2A 884/4885 |
| US-20160303123-A1 | CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIKFYVE, PI4KA, PIP4K2B | THRB 2047/4885MAPT 4705/4885KMT2A 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.